CLRB beat EPS expectations by 91.47%
Nov 08, 2024, 11:31 AM
-25.27%
What does CLRB do
Cellectar Biosciences, based in Florham Park, New Jersey, develops phospholipid drug conjugates for cancer treatment and imaging, with a focus on targeted therapies and a pipeline including iopofosine. The company went public on May 20, 2005, and employs 20 staff.
Cellectar Biosciences (CLRB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cellectar Biosciences's actual EPS was -$0.03, beating the estimate of -$0.35 per share, resulting in a 91.47% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.